Scientists Embed Microchips Directly into Brain Tissue Using Immune Cells

Researchers led by Deblina Sarkar, an electrical engineer and MIT assistant professor, have successfully developed microscopic electronic devices that can be injected into the circulatory system and implant themselves in target brain areas. These devices, which are hybridized with living cells, can travel through the bloodstream before reaching their intended destination, eliminating the need for surgical procedures typically required for brain implants. According to Sarkar, the team faced significant challenges in the early stages of their research, with 35 grant proposals being rejected in a row. Reviewers deemed the idea "very impactful, but impossible," a notion that Sarkar acknowledges was not unfounded, given the proposal's science fiction-like nature. However, after more than six years of research, the team has made significant breakthroughs, with initial data gathered in 2022 yielding promising results. The technology, which involves using nanobots to deliver electronic devices to specific areas of the brain, has the potential to revolutionize the field of neurology and beyond. Sarkar's team has been working on this project at MIT, where they have made significant advancements in the development of these microscopic devices. The devices are designed to be injected into the circulatory system using a standard syringe, allowing them to travel through the bloodstream before implanting themselves in target brain areas. The development of these devices has significant implications for the treatment of neurological disorders, such as Parkinson's disease and epilepsy. Traditional brain implants require surgical procedures, which can be invasive and carry risks. The ability to deliver these devices through a non-invasive means could greatly improve treatment outcomes and reduce the risk of complications. Sarkar's team has been working closely with neurologists and other medical professionals to ensure that the technology is safe and effective. The devices are designed to be biocompatible and non-toxic, and the team has conducted extensive testing to ensure that they do not cause any adverse reactions. While the technology is still in its early stages, Sarkar and her team are optimistic about its potential. "We're not just talking about treating neurological disorders," Sarkar said. "We're talking about revolutionizing the way we approach medicine and healthcare." The team is currently working on refining the technology and preparing it for clinical trials. The success of Sarkar's team has sparked interest in the scientific community, with many researchers and clinicians seeing the potential for this technology to transform the field of medicine. As the technology continues to develop, it is likely that we will see significant advancements in the treatment of neurological disorders and beyond.